Xponance Inc. Purchases 445 Shares of LivaNova PLC (NASDAQ:LIVN)

Xponance Inc. increased its position in shares of LivaNova PLC (NASDAQ:LIVN) by 6.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,762 shares of the company’s stock after purchasing an additional 445 shares during the period. Xponance Inc.’s holdings in LivaNova were worth $359,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of LIVN. Swiss National Bank lifted its position in shares of LivaNova by 0.7% in the fourth quarter. Swiss National Bank now owns 106,819 shares of the company’s stock valued at $4,947,000 after acquiring an additional 700 shares in the last quarter. Central Pacific Bank Trust Division lifted its holdings in LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after purchasing an additional 720 shares in the last quarter. Amalgamated Bank boosted its stake in LivaNova by 3.0% in the 4th quarter. Amalgamated Bank now owns 24,900 shares of the company’s stock worth $1,153,000 after purchasing an additional 729 shares during the period. Rhumbline Advisers grew its holdings in LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock valued at $8,240,000 after buying an additional 899 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of LivaNova by 29.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company’s stock valued at $292,000 after buying an additional 1,424 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Stifel Nicolaus cut their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Barclays reduced their target price on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a report on Friday, March 7th. StockNews.com raised LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Finally, Mizuho lowered their target price on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $61.17.

LivaNova Stock Performance

NASDAQ:LIVN opened at $39.90 on Thursday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The stock’s fifty day moving average is $44.86 and its 200 day moving average is $48.58. The firm has a market capitalization of $2.17 billion, a PE ratio of 95.00 and a beta of 1.10. LivaNova PLC has a fifty-two week low of $36.85 and a fifty-two week high of $64.48.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.